Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tallysomycin S10b--a phase I trial.

P G Sørensen1, H Pedersen, H V Clausen

  • 1Department of Oncology II, Finsen Institute, Copenhagen, Denmark.

Cancer Chemotherapy and Pharmacology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of alternative feed additives to medicinal zinc oxide on productivity, diarrhoea incidence and gut development in weaned piglets.

Animal : an international journal of animal bioscience·2020
Same author

Evaluation of the feeding value of Dichrostachys cinerea pods for fattening pigs in Cuba.

Tropical animal health and production·2017
Same author

High plasma triglyceride levels strongly correlate with low kisspeptin in the arcuate nucleus of male rats.

Endocrine regulations·2015
Same author

Technical note: In vitro total gas and methane production measurements from closed or vented rumen batch culture systems.

Journal of dairy science·2014
Same author

Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain.

Developmental neuroscience·2010
Same author

The medullary nail presentation of a new type and report of a case.

Archives of surgery (Chicago, Ill. : 1920)·2010

Tallysomycin S10b, a bleomycin analogue, showed similar antineoplastic activity but less renal toxicity in early human trials. Pulmonary toxicity, not renal, emerged as dose-limiting, with a recommended Phase II dose of 2.5 mg/m2.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Tallysomycin S10b is a novel bleomycin analogue with promising antineoplastic activity in preclinical models.
  • Animal studies indicated lower pulmonary and higher renal toxicity compared to bleomycin.

Purpose of the Study:

  • To evaluate the safety and tolerability of tallysomycin S10b in cancer patients.
  • To determine the dose-limiting toxicities and establish a recommended dose for Phase II trials.

Main Methods:

  • A Phase I dose-escalation study involving 16 patients treated with tallysomycin S10b at 1.25, 2.5, or 5 mg/m2 intravenously twice weekly.
  • Regular monitoring included chest X-rays, pulmonary function tests, renography, and 51Cr-EDTA clearance.

Main Results:

Related Experiment Videos

  • No renal toxicity was observed. Pulmonary toxicity, including decreased DLCO and interstitial pneumonitis, was dose-limiting at higher doses (5 mg/m2).
  • Common side effects like skin changes, stomatitis, and fever increased with cumulative dose, similar to bleomycin.
  • No tumor regression was observed in this trial.

Conclusions:

  • Pulmonary toxicity, not renal toxicity, is the dose-limiting factor for tallysomycin S10b in humans.
  • A dose of 2.5 mg/m2 twice weekly is recommended for further Phase II trials, with close pulmonary function monitoring.